Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Global Small Caps Initiates Coverage on Nutra Pharma
February 22, 2017

February 22, 2017 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.

The report is available at: http://tinyurl.com/NPHCreport

"We certainly appreciate any coverage of our company, especially as it pertains to the work that we are doing and the potential growth in shareholder value," commented Rik J Deitsch, CEO of Nutra Pharma. “We have been getting a lot of press lately. In fact, we were recently featured on NBC News Miami in a piece that has since been picked up nationally," he continued. "The current report on Global Small Caps focusses on our OTC pain drugs, Nyloxin and Pet Pain-Away. These are clinically proven, all-natural products that are available today to deal with pain and inflammation in people and their pets. The report also outlines the future of the Company’s drug platform, especially the opportunity with our Multiple Sclerosis drug, RPI-78M," he concluded.

According to their website, Global Small Caps, LLC is an independent company that researches public small caps in order to bring the latest investment trends to the average investor.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The report by Global Small Caps should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
March 14, 2017
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


February 22, 2017
Global Small Caps Initiates Coverage on Nutra Pharma


February 15, 2017
Nutra Pharma and Nyloxin Featured on NBC News-Miami


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics